Oppenheimer Asset Management Inc. boosted its holdings in PetIQ, Inc. (NASDAQ:PETQ – Get Rating) by 12.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,085 shares of the company’s stock after buying an additional 1,209 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in PetIQ were worth $186,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Fulcrum Asset Management LLP acquired a new position in shares of PetIQ in the 1st quarter worth $1,574,000. Acuitas Investments LLC purchased a new position in PetIQ in the 1st quarter worth about $3,628,000. Amalgamated Bank acquired a new stake in PetIQ during the 1st quarter worth about $107,000. Swiss National Bank lifted its stake in PetIQ by 8.3% during the first quarter. Swiss National Bank now owns 58,600 shares of the company’s stock valued at $1,430,000 after buying an additional 4,500 shares in the last quarter. Finally, Boston Partners boosted its holdings in shares of PetIQ by 1.9% in the first quarter. Boston Partners now owns 1,570,477 shares of the company’s stock worth $38,264,000 after buying an additional 29,205 shares during the period.
Analysts Set New Price Targets
Several brokerages recently commented on PETQ. Jefferies Financial Group reduced their price target on shares of PetIQ to $21.00 in a research report on Wednesday, September 21st. Raymond James reduced their target price on PetIQ from $21.00 to $16.00 and set an “outperform” rating for the company in a report on Tuesday, October 25th.
PetIQ Price Performance
PetIQ (NASDAQ:PETQ – Get Rating) last released its quarterly earnings data on Wednesday, November 9th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.12. The firm had revenue of $209.73 million for the quarter, compared to analyst estimates of $203.90 million. PetIQ had a negative net margin of 5.94% and a positive return on equity of 10.46%. Equities research analysts expect that PetIQ, Inc. will post 0.87 EPS for the current fiscal year.
PetIQ Company Profile
PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications.
- Get a free copy of the StockNews.com research report on PetIQ (PETQ)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.